Medytox Temporarily Suspends Manufacturing and Sales of Meditoxin and Coretox Stocks Worth 104.9 Billion KRW
[Asia Economy Reporter Geum Bo-ryeong] Medytox announced on the 20th that it will temporarily suspend the manufacturing and sales of Meditoxin Injection (Clostridium botulinum toxin type A) and Coretox Injection (Clostridium botulinum toxin type A (150kDa)).
The amount affected by the suspension is approximately 104.9 billion KRW, which accounts for 50.93% of last year's consolidated sales.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Medytox stated, "We received a notification from the Daejeon Regional Food and Drug Administration ordering the temporary suspension of manufacturing and sales for the pharmaceuticals confirmed to have been sold without national batch approval, pursuant to Article 71 of the Pharmaceutical Affairs Act." They added, "We plan to file for a suspension of execution and a lawsuit to cancel the order at the Daejeon District Court."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
